In Brief: Myriad Genetics Laboratories
This article was originally published in The Gray Sheet
Executive Summary
Myriad Genetics Laboratories: Begins long-term study with the American College of Surgeons to evaluate outcomes of patients undergoing BRCA1 genetic analysis for breast and ovarian cancer susceptibility. The ACS-Myriad BRCA1 Longitudinal Study (AMBLS) will use Myriad's BRACAone genetic analysis test, which is slated for full commercial launch later this year ("The Gray Sheet" July 22, In Brief), and the firm's "multi-center, patient database to obtain mutation incidence and clinical data." The "major questions" to be addressed by the study include: "which BRCA1 mutations are strongly penetrant (have a strong correlation to the risk of getting the disease); and what is the likely clinical outcome after medical and surgical intervention"...